Philadelphia, November 24, 2025
Ladder Bio Inc., formerly ThirdLaw Molecular, has announced a strategic rebranding and secured $5.5 million in Series Seed funding to advance its Spiroligomer™ platform. The new CEO, Eric Heil, along with new board members, positions the company for growth in developing therapeutics targeting hard-to-drug proteins. This significant funding will support scaling operations and innovate within the biotechnology sector, reflecting Philadelphia’s dynamic entrepreneurial spirit.
Philadelphia, PA – Ladder Bio Inc., formerly known as ThirdLaw Molecular, has launched a strategic rebranding alongside securing $5.5 million in Series Seed funding aimed at advancing its innovative Spiroligomer™ platform. The company’s initiative focuses on developing a new class of therapeutics specifically targeting disease-causing proteins that have historically been labeled as “undruggable.”
This rebranding signifies Ladder Bio’s commitment to pioneering “ladder-shaped,” peptide-like molecules that aim to blend the potency and specificity of biologics with the stability and oral availability of small molecules. These advancements are particularly crucial for addressing conditions where traditional drug modalities have failed to deliver effective treatments.
The company has appointed experienced healthcare executive Eric Heil as the new CEO. Heil’s extensive background in the industry is expected to guide Ladder Bio’s growth trajectory effectively. Moreover, industry professionals David Scheer and Dr. Brian Halak have joined the Board of Directors, enhancing the company’s strategic leadership during this transformative phase.
### Funding Details and Plans for Growth
The recent funding round, spearheaded by Medical Excellence Capital and supported by Hatch BioFund, marks a significant moment for Ladder Bio. The $5.5 million raised will be directed towards scaling the Spiroligomer platform, validating lead programs, initiating early in vitro studies, and expanding both the scientific and development teams.
Ladder Bio’s Spiroligomer technology is designed to occupy a unique chemical space, capturing the critical advantages of biologics while offering the stability and oral dosing benefits commonly found in small molecules. The company believes that this innovative approach could unlock new therapeutic pathways for various conditions where current technologies have often fallen short.
### Leadership Transition and Strategic Vision
The recent leadership appointments reflect decades of experience across biopharma development, venture investment, and operational strategy. This seasoned expertise is integral to guiding the company as it moves into its next stage of development.
– Eric Heil takes the helm as CEO, bringing an extensive portfolio of healthcare-related operations and strategic insights.
– David Scheer and Dr. Brian Halak join the Board of Directors, lending their expertise to bolster Ladder Bio’s strategic initiatives.
These leadership enhancements not only strengthen the company’s internal framework but also align with its ambitious goals of innovating within the biotechnology sector.
### Benefits of the Spiroligomer Technology
The Spiroligomer™ platform aims to engineer molecules that exhibit unique characteristics, such as structural rigidity and sequence definition. This specificity aims to elevate the therapeutic potential beyond the limitations of existing drug modalities, setting Ladder Bio apart in a competitive landscape.
The extensive funding and enhanced leadership aim to harness the potential of this technology, along with proactive steps towards validating its applications in clinical settings. This stands as a testament to the resilient spirit of Philadelphia’s entrepreneurial ecosystem, where innovative ideas are cultivated with minimal regulatory obstacles and robust private investments.
### Conclusion
Ladder Bio’s rebranding and funding acquisition highlight the dynamic nature of Philadelphia’s biotechnology sector and the increasing trend of local entrepreneurs harnessing innovative technologies to address complex medical challenges. These developments not only signal a commitment to improving healthcare outcomes but also underscore the importance of fostering a supportive environment for business growth and innovation.
As Ladder Bio embarks on this journey, the Philadelphia community is encouraged to support local businesses and engage in the broader narrative of economic growth.
Frequently Asked Questions (FAQ)
What is Ladder Bio Inc.?
Ladder Bio Inc., formerly known as ThirdLaw Molecular, is a biotechnology company focused on developing a new class of therapeutics using its Spiroligomer™ platform to target disease-causing proteins previously considered “undruggable.”
What is the Spiroligomer™ platform?
The Spiroligomer™ platform is a proprietary technology that engineers “ladder-shaped,” peptide-like molecules designed to combine the potency and specificity of biologics with the stability and oral availability of small molecules, aiming to address conditions where traditional drug modalities have been ineffective.
Who are the new leadership appointments at Ladder Bio?
Eric Heil has been appointed as the new CEO, with industry leaders David Scheer and Dr. Brian Halak joining the Board of Directors.
How much funding did Ladder Bio secure?
Ladder Bio secured $5.5 million in Series Seed funding, led by Medical Excellence Capital and with participation from Hatch BioFund.
What are the plans for the funding?
The funding will be used to scale the Spiroligomer platform, validate lead programs, initiate early in vitro studies, and expand the scientific and development teams.
Key Features of Ladder Bio’s Initiative
| Feature | Description |
|---|---|
| Rebranding | ThirdLaw Molecular rebranded to Ladder Bio Inc. to better reflect its mission. |
| Funding | Secured $5.5 million in Series Seed funding led by Medical Excellence Capital. |
| Leadership | Appointed Eric Heil as CEO; David Scheer and Dr. Brian Halak joined the Board of Directors. |
| Spiroligomer™ Platform | Developing “ladder-shaped,” peptide-like molecules targeting “undruggable” disease-causing proteins. |
| Funding Allocation | Plans to scale the platform, validate lead programs, initiate early in vitro studies, and expand teams. |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE PHILADELPHIA WRITER
The PHILADELPHIA STAFF WRITER represents the experienced team at HEREPhiladelphia.com, your go-to source for actionable local news and information in Philadelphia, Philadelphia County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Mummers Parade, Philadelphia Flower Show, and Thanksgiving Day Parade. Our coverage extends to key organizations like the Greater Philadelphia Chamber of Commerce and United Way of Greater Philadelphia, plus leading businesses in telecommunications, food services, and healthcare that power the local economy such as Comcast, Aramark, and Children's Hospital of Philadelphia. As part of the broader HERE network, we provide comprehensive, credible insights into Pennsylvania's dynamic landscape.
